Serpin induced antiviral activity of prostaglandin synthetase-2 against HIV-1 replication

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Whitney, James B ^a,b   Asmal, Mohammed ^a,b   Geiben Lynn, Ralf ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN ACTIVATED ANTITHROMBIN III; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE 2; RECOMBINANT ANTITHROMBIN III; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; INNATE IMMUNITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SIGNAL TRANSDUCTION; VIRUS INHIBITION; VIRUS REPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; PHYSIOLOGY; WESTERN BLOTTING;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; SIMPLEXVIRUS;

ANTIVIRAL AGENTS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV-1; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SERPINS; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

EID: 79954558340     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018589     Document Type: Article

References (34)

1. Opal SM, Esmon CT, (2003) Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care 7: 23-38.
2. Feistritzer C, Wiedermann CJ, (2007) Effects of anticoagulant strategies on activation of inflammation and coagulation. Expert Opin Biol Ther 7: 855-870.
3. Rawlings ND, Tolle DP, Barrett AJ, (2004) Evolutionary families of peptidase inhibitors. Biochem J 378: 705-716.
4. Irving JA, Pike RN, Lesk AM, Whisstock JC, (2000) Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function. Genome Res 10: 1845-1864.
5. Irving JA, Steenbakkers PJ, Lesk AM, Op den Camp HJ, Pike RN, et al. (2002) Serpins in prokaryotes. Mol Biol Evol 19: 1881-1890.
6. Steenbakkers PJ, Irving JA, Harhangi HR, Swinkels WJ, Akhmanova A, et al. (2008) A serpin in the cellulosome of the anaerobic fungus Piromyces sp. strain E2. Mycol Res 112: 999-1006.
7. Duru S, Koca U, Oztekin S, Olguner C, Kar A, et al. (2005) Antithrombin III pretreatment reduces neutrophil recruitment into the lung and skeletal muscle tissues in the rat model of bilateral lower limb ischemia and reperfusion: a pilot study. Acta Anaesthesiol Scand 49: 1142-1148.
8. Aytekin FO, Tekin K, Kabay B, Erdem E, Guney Y, et al. (2005) Antithrombin III attenuates pulmonary tissue injury caused by mesenteric ischemia-reperfusion. Am J Surg 189: 161-166.
9. Tsuboi H, Naito Y, Katada K, Takagi T, Handa O, et al. (2007) Role of the thrombin/protease-activated receptor 1 pathway in intestinal ischemia-reperfusion injury in rats. Am J Physiol Gastrointest Liver Physiol 292: G678-683.
10. Ostrovsky L, Woodman RC, Payne D, Teoh D, Kubes P, (1997) Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 96: 2302-2310.
11. Hoffmann JN, Vollmar B, Inthorn D, Schildberg FW, Menger MD, (2000) Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway. Am J Physiol Cell Physiol 279: C98-C107.
12. Chan ED, Kaminska AM, Gill W, Chmura K, Feldman NE, et al. (2007) Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages. Scand J Infect Dis 39: 690-696.
13. Hashemi M, Naderi M, Rashidi H, Ghavami S, (2007) Impaired activity of serum alpha-1-antitrypsin in diabetes mellitus. Diabetes Res Clin Pract 75: 246-248.
14. O'Riordan K, Blei A, Rao MS, Abecassis M, (1997) alpha 1-antitrypsin deficiency-associated panniculitis: resolution with intravenous alpha 1-antitrypsin administration and liver transplantation. Transplantation 63: 480-482.
15. Potthoff AV, Munch J, Kirchhoff F, Brockmeyer NH, (2007) HIV infection in a patient with alpha-1 antitrypsin deficiency: a detrimental combination? AIDS 21: 2115-2116.
16. Shapiro L, Pott GB, Ralston AH, (2001) Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1. FASEB J 15: 115-122.
17. Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H, (2009) The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat 16: 418-429.
18. McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, et al. (1997) Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 90: 1141-1149.
19. Burgener A, Boutilier J, Wachihi C, Kimani J, Carpenter M, et al. (2008) Identification of differentially expressed proteins in the cervical mucosa of HIV-1-resistant sex workers. J Proteome Res 7: 4446-4454.
20. Geiben-Lynn R, Brown N, Walker BD, Luster AD, (2002) Purification of a modified form of bovine antithrombin III as an HIV-1 CD8+ T-cell antiviral factor. J Biol Chem 277: 42352-42357.
21. Elmaleh DR, Brown NV, Geiben-Lynn R, (2005) Anti-viral activity of human antithrombin III. Int J Mol Med 16: 191-200.
22. Sidwell RW, Huffman JH, (1971) Use of disposable micro tissue culture plates for antiviral and interferon induction studies. Appl Microbiol 22: 797-801.
23. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, et al. (1972) Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177: 705-706.
24. Geiben-Lynn R, Kursar M, Brown NV, Kerr EL, Luster AD, et al. (2001) Noncytolytic inhibition of ×4 virus by bulk CD8(+) cells from human immunodeficiency virus type 1 (HIV-1)-infected persons and HIV-1-specific cytotoxic T lymphocytes is not mediated by beta-chemokines. J Virol 75: 8306-8316.
25. Barnard DL, Huffman JH, Meyerson LR, Sidwell RW, (1993) Mode of inhibition of respiratory syncytial virus by a plant flavonoid, SP-303. Chemotherapy 39: 212-217.
26. Barnard DL, Stowell VD, Seley KL, Hegde VR, Das SR, et al. (2001) Inhibition of measles virus replication by 5′-nor carbocyclic adenosine analogues. Antivir Chem Chemother 12: 241-250.
27. Ikeda M, Abe K, Dansako H, Nakamura T, Naka K, et al. (2005) Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. Biochem Biophys Res Commun 329: 1350-1359.
28. Drusano GL, Prichard M, Bilello PA, Bilello JA, (1996) Modeling combinations of antiretroviral agents in vitro with integration of pharmacokinetics: guidance in regimen choice for clinical trial evaluation. Antimicrob Agents Chemother 40: 1143-1147.
29. Collman R, Balliet JW, Gregory SA, Friedman H, Kolson DL, et al. (1992) An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol 66: 7517-7521.
30. Sauri H, Ashjian PH, Kim AT, Shau H, (1996) Recombinant natural killer enhancing factor augments natural killer cytotoxicity. J Leukoc Biol 59: 925-931.
31. Koulmanda M, Bhasin M, Hoffman L, Fan Z, Qipo A, et al. (2008) Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci U S A 105: 16242-16247.
32. Kramer HB, Lavender KJ, Qin L, Stacey AR, Liu MK, et al. Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection. PLoS Pathog 6: e1000893.
33. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, et al. (1995) Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 96: 456-464.
34. Hughes-Fulford M, McGrath MS, Hanks D, Erickson S, Pulliam L, (1992) Effects of dimethyl prostaglandin A1 on herpes simplex virus and human immunodeficiency virus replication. Antimicrob Agents Chemother 36: 2253-2258.